H Hasle

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
    H Hasle
    Department of Pediatrics, Skejby Hospital, Aarhus, Denmark
    Leukemia 17:277-82. 2003
  2. ncbi request reprint Myelodysplastic and myeloproliferative disorders in children
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Curr Opin Pediatr 19:1-8. 2007
  3. ncbi request reprint Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark
    Blood 120:978-84. 2012
  4. ncbi request reprint Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Blood 109:4641-7. 2007
  5. doi request reprint Malignant diseases in Noonan syndrome and related disorders
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Denmark
    Horm Res 72:8-14. 2009
  6. ncbi request reprint Pattern of malignant disorders in individuals with Down's syndrome
    H Hasle
    Department of Paediatrics, Skejby Hospital, Aarhus University, Denmark
    Lancet Oncol 2:429-36. 2001
  7. ncbi request reprint [Occurrence of cancer in individuals with Down syndrome]
    H Hasle
    Arhus Universitetshospital, Skejby Sygehus
    Ugeskr Laeger 162:4535-9. 2000
  8. doi request reprint Advances in the prognostication and management of advanced MDS in children
    Henrik Hasle
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 154:185-95. 2011
  9. ncbi request reprint The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
    H Hasle
    Department of Pediatrics, Skejby Hospital, Aarhus University, Denmark
    Leukemia 18:2008-14. 2004
  10. doi request reprint Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia
    Lene Molgaard-Hansen
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 152:623-30. 2011

Collaborators

Detail Information

Publications36

  1. ncbi request reprint A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
    H Hasle
    Department of Pediatrics, Skejby Hospital, Aarhus, Denmark
    Leukemia 17:277-82. 2003
    ..Cytogenetics and serial assessments of the patients are essential adjuncts to morphology both in diagnosis and classification...
  2. ncbi request reprint Myelodysplastic and myeloproliferative disorders in children
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Curr Opin Pediatr 19:1-8. 2007
    ..A number of significant advances have been achieved in recent years. The present review will focus on diagnostics and therapy...
  3. ncbi request reprint Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark
    Blood 120:978-84. 2012
    ..In conclusion, GO therapy postconsolidation as given in this trial was well tolerated, showed a nonsignificant delay in time to relapse, but did not change the rate of relapse or survival (clinicaltrials.gov identifier NCT00476541)...
  4. ncbi request reprint Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Blood 109:4641-7. 2007
    ..Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future risk-group stratification...
  5. doi request reprint Malignant diseases in Noonan syndrome and related disorders
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Denmark
    Horm Res 72:8-14. 2009
    ..Registry-based studies of patients with NS and related disorders diagnosed with molecular genetics and a high-quality long-term follow-up are necessary to further estimate the incidence of malignancy...
  6. ncbi request reprint Pattern of malignant disorders in individuals with Down's syndrome
    H Hasle
    Department of Paediatrics, Skejby Hospital, Aarhus University, Denmark
    Lancet Oncol 2:429-36. 2001
    ..Increased susceptibility to apoptosis in DS may result in cell death rather than malignant transformation after major cell injuries. This hypothesis would explain the decreased risk of both solid tumours and secondary cancers...
  7. ncbi request reprint [Occurrence of cancer in individuals with Down syndrome]
    H Hasle
    Arhus Universitetshospital, Skejby Sygehus
    Ugeskr Laeger 162:4535-9. 2000
    ..The distinctive pattern of malignancies may provide clues in the search for leukaemogenic genes and tumour suppressor genes on chromosome 21...
  8. doi request reprint Advances in the prognostication and management of advanced MDS in children
    Henrik Hasle
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 154:185-95. 2011
    ..Intensive chemotherapy before HSCT should be considered in patients with myelodysplasia-related-AML (MDR-AML)...
  9. ncbi request reprint The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
    H Hasle
    Department of Pediatrics, Skejby Hospital, Aarhus University, Denmark
    Leukemia 18:2008-14. 2004
    ..In conclusion, the IPSS is of limited value in both pediatric MDS and JMML. The results reflect the differences between myelodysplastic and myeloproliferative diseases in children and adults...
  10. doi request reprint Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia
    Lene Molgaard-Hansen
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 152:623-30. 2011
    ..Fourteen (82%) of 17 TRDs occurred in children undergoing haematopoietic stem cell transplantations (HSCT). Optimal supportive care after HSCT is essential, and studies on risk factors for TRD are needed...
  11. ncbi request reprint Risks of leukaemia and solid tumours in individuals with Down's syndrome
    H Hasle
    Department of Paediatrics, Aarhus University Hospital Skejby, Denmark
    Lancet 355:165-9. 2000
    ..Individuals with Down's syndrome have a greater risk of leukaemia than the general population, but reliable estimates of the age-specific risk are lacking and little is known about the risk of solid tumours...
  12. pmc Occurrence of cancer in women with Turner syndrome
    H Hasle
    Department of Paediatrics, Odense University Hospital, Denmark
    Br J Cancer 73:1156-9. 1996
    ..Colon cancer was observed in five patients (relative risk 6.9, 95% confidence interval 2.2-16.2). Further studies are needed to assess whether colon cancer in TS is related to Turner-associated genes on the sex chromosome(s)...
  13. ncbi request reprint Evidence of decreased risk of cancer in individuals with fragile X
    S Schultz-Pedersen
    Department of Pediatrics, Viborg Hospital, Viborg, Denmark
    Am J Med Genet 103:226-30. 2001
    ..28 (95% confidence interval: 0.1-0.8). The possibility that the expanded trinucleotide repeats in fragile X syndrome protect against cancer is discussed...
  14. pmc Cancer incidence in men with Klinefelter syndrome
    H Hasle
    Department of Paediatrics, Odense University Hospital, Denmark
    Br J Cancer 71:416-20. 1995
    ..The overall cancer incidence is not increased and no routine cancer screening seems to be justified. A considerably elevated risk of mediastinal germ cell tumours occurs in the period from early adolescence until the age of 30...
  15. ncbi request reprint A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada
    H Hasle
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 106:1027-32. 1999
    ..Data on MDS from treatment-based studies and cancer registries were inaccurate and seemed to significantly underestimate the incidence of MDS in children...
  16. doi request reprint Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003
    Lene Molgaard-Hansen
    Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Br J Haematol 151:447-59. 2010
    ..The number of EDs and TRDs in AML is high. Therefore optimal antifungal prophylaxis is essential, and studies on the benefit of antibacterial prophylaxis and individual risk factors for ED and TRD are needed...
  17. ncbi request reprint Improved outcome after relapse in children with acute myeloid leukaemia
    Jonas Abrahamsson
    Department of Clinical Sciences, Queen Silvia s Childrens Hospital, Gothenburg, Sweden
    Br J Haematol 136:229-236. 2007
    ..A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%...
  18. ncbi request reprint WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study
    Mette Østergaard
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 125:590-600. 2004
    ..We conclude that WT1 expression by RQ-PCR may be employed as a tool to detect MRD in the majority of fusion transcript-negative AML patients...
  19. ncbi request reprint Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials
    Sverre O Lie
    Department of Paediatrics, University Hospital, Rikshospitalet, Oslo, Norway
    Br J Haematol 122:217-25. 2003
    ..The overall outcome was improved by employing the previous toxic protocol with different timings, and through individualizing therapy according to the initial response of the patient...
  20. ncbi request reprint Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature
    Lotte Abildgaard
    Department of Paediatrics, Skejby Hospital, 8200, Aarhus N, Denmark
    Ann Hematol 85:275-80. 2006
    ..Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS...
  21. ncbi request reprint Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse
    Jesper Stentoft
    Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, DK 8000 Aarhus C, Denmark
    Leuk Res 30:389-95. 2006
    ..This direct comparison between the two subgroups of CBF AMLs delineates clear biological differences and corroborates the value of RQ-PCR...
  22. ncbi request reprint Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
    Franco Locatelli
    Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Blood 105:410-9. 2005
    ..Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling...
  23. ncbi request reprint Pediatric myelodysplastic syndromes
    Charlotte Marie Niemeyer
    Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany
    Curr Treat Options Oncol 6:209-14. 2005
    ..Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly...
  24. ncbi request reprint Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7
    Gabriela Kardos
    Division of Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Mathildenstrasse 1, 79106 Freiburg, Germany
    Blood 102:1997-2003. 2003
    ..Recommendations for best treatment options for children with other chromosomal abnormalities or normal karyotype may have to await results of prospective clinical trials...
  25. doi request reprint Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals
    Hans Beier Ommen
    The Laboratory of Immunohematology, Department of Haematology, Arhus University Hospital, Arhus, Denmark
    Br J Haematol 141:782-91. 2008
    ..In conclusion, CR1 WT1 expression is an independent prognostic factor in AML. According to our model, BM is superior for relapse prediction, but PB samples are useful when shorter sampling intervals are possible...
  26. ncbi request reprint Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome
    Alice Norton
    Blood 110:1077-9. 2007
  27. ncbi request reprint Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
    Marco Tartaglia
    Department of Pediatrics, Mount Sinai School of Medicine, New York, New York, USA
    Nat Genet 34:148-50. 2003
    ..Functional analyses documented that the two most common mutations in PTPN11 associated with JMML caused a gain of function...
  28. ncbi request reprint Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: a double-blinded study
    Birgitte Klug Albertsen
    Department of Pharmacology, The Bartholin Building, University of Aarhus, Denmark
    Pediatr Blood Cancer 44:255-8. 2005
    ..To evaluate if dissolution of asparaginase in lidocaine can relieve pain of an intramuscular injection in children without changes in bioavailability...
  29. ncbi request reprint Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria
    Eva Bergstraesser
    Division of Pediatric Hematology and Oncology, University Children s Hospital Zurich, Zurich, Switzerland
    Pediatr Blood Cancer 49:629-33. 2007
    ..Classification schemas applied in other forms of leukemia are of little value, because in JMML therapy may result in divergent responses in solid organs compared to peripheral blood (PB)...
  30. ncbi request reprint Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT
    Birgitte S Preiss
    Institute of Pathology Laboratory of Molecular Pathology and Chromosome Laboratory, Odense University Hospital, Odense C DK 5000, Denmark
    Cancer Genet Cytogenet 165:1-8. 2006
    ..Genetic techniques complement each other and selection of relevant and targeted primer kits for the multiplex RT-PCR assay is recommended...
  31. ncbi request reprint Population-based study of cancer among carriers of a constitutional structural chromosomal rearrangement
    Iben Bache
    Wilhelm Johannsen Centre for Functional Genome Research, Department of Medical Biochemistry and Genetics, University of Copenhagen, Denmark
    Genes Chromosomes Cancer 45:231-46. 2006
    ..Molecular mapping of these breakpoints might provide new insight into cancer predisposition...
  32. ncbi request reprint WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder
    Henrik Hasle
    Department of Pediatrics, Skejby Hospital, DK 8200 Aarhus N, Denmark
    Leuk Res 30:543-6. 2006
    ..The lack of normalization of WT1 level may be a predictor of leukemia development and WT1 expression may be an attractive marker for monitoring of minimal residual disease...
  33. ncbi request reprint Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001
    Merete Stubkjaer Christensen
    Department of Paediatrics, Skejby Hospital, Aarhus, Denmark
    Br J Haematol 131:50-8. 2005
    ..00). In conclusion, 3% of children with ALL died of TRD, with bacterial infections as the most common cause of death. Girls and Down syndrome patients had a higher risk of TRD. Infections still remain a major challenge in childhood ALL...
  34. pmc The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
    Christian P Kratz
    University of California, Room HSE 302 Box 0519, San Francisco, CA 94143, USA
    Blood 106:2183-5. 2005
    ..This supports the need to characterize the spectrum of hematologic abnormalities in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in patients with NS/MPD and JMML...
  35. ncbi request reprint Acute leukaemia in children with Down syndrome: a population-based Nordic study
    Bernward Zeller
    Department of Paediatrics, National Hospital of Norway, N 0027 Oslo, Norway
    Br J Haematol 128:797-804. 2005
    ..The high proportion of female DS patients with AML is unexplained. The differing treatment results in AML versus ALL need further evaluation and represent a challenge for the coming years...
  36. ncbi request reprint Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance
    Marianne Hutchings Hoffmann
    Haematologica 90:984-6. 2005
    ..In five patients, a cytogenetically unrevealed fusion gene of prognostic importance was detected, while the assay failed to detect one case of t(15;17)...